Wockhardt soars as USFDA accepts NDA for antibiotic Zaynich
Wockhardt is currently trading at Rs. 1504.25, up by 33.35 points or 2.27% from its previous closing of Rs. 1470.90 on the BSE.
The scrip opened at Rs. 1492.95 and has touched a high and low of Rs. 1566.95 and Rs. 1467.80 respectively. So far 1102017 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1870.00 on 12-Jun-2025 and a 52 week low of Rs. 1109.60 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs. 1566.95 and Rs. 1226.15 respectively. The current market cap of the company is Rs. 24429.07 crore.
The promoters holding in the company stood at 49.08%, while Institutions and Non-Institutions held 18.12% and 32.80% respectively.
The United States Food and Drug Administration (USFDA) has formally accepted Wockhardt’s New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich. The NDA was originally filed on September 30, 2025, and its acceptance marks a transformative moment for the entire Indian pharmaceutical industry. This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA.
Zaynich has been granted Fast Track designation by the USFDA, recognizing its potential to address urgent and unmet medical needs. As part of this pathway, the FDA has committed to assign priority to Zaynich NDA review. A novel β-lactam enhancer mechanism based Zaynich has garnered international attention for its potent activity against highly resistant Gram-negative pathogens - microbes responsible for prolonged hospitalizations and significant mortality worldwide. Its life-saving impact has already been demonstrated through compassionate use in critically ill patients in both India and the United States.
Wockhardt is a research based Global Pharmaceutical and Biotech company.
